Carrell R W, Stein P E, Fermi G, Wardell M R
Department of Haematology, University of Cambridge, UK.
Structure. 1994 Apr 15;2(4):257-70. doi: 10.1016/s0969-2126(00)00028-9.
Antithrombin, a member of the serpin family of inhibitors, controls coagulation in human plasma by forming complexes with thrombin and other coagulation proteases in a process greatly accelerated by heparin. The structures of several serpins have been determined but not in their active conformations. We have determined the structure of intact antithrombin in order to study its mechanism of activation, particularly with respect to heparin, and the dysfunctions of this mechanism that predispose individuals to thrombotic disease.
The crystal structure of a dimer of one active and one inactive molecule of antithrombin has been determined at 3 A. The first molecule has its reactive-centre loop in a predicted active conformation compatible with initial entry of two residues into the main beta-sheet of the molecule. The inactive molecule has a totally incorporated loop as in latent plasminogen activator inhibitor-1. The two molecules are linked by the reactive loop of the active molecule which has replaced a strand from another beta-sheet in the latent molecule.
The structure, together with identified mutations affecting its heparin affinity, allows the placement of the heparin-binding site on the molecule. The conformation of the two forms of antithrombin demonstrates the extraordinary mobility of the reactive loop in the serpins and provides insights into the folding of the loop required for inhibitory activity together with the potential modification of this by heparin. The mechanism of dimerization is relevant to the polymerization that is observed in diseases associated with variant serpins.
抗凝血酶是丝氨酸蛋白酶抑制剂家族的成员之一,通过与凝血酶及其他凝血蛋白酶形成复合物来控制人体血浆中的凝血过程,肝素可极大加速这一过程。已确定了几种丝氨酸蛋白酶抑制剂的结构,但并非其活性构象。我们测定了完整抗凝血酶的结构,以研究其激活机制,特别是与肝素相关的机制,以及该机制的功能障碍,这些功能障碍使个体易患血栓性疾病。
已在3埃分辨率下测定了一个活性抗凝血酶分子和一个非活性抗凝血酶分子二聚体的晶体结构。第一个分子的反应中心环处于预测的活性构象,与两个残基最初进入分子的主要β折叠相兼容。非活性分子具有一个完全嵌入的环,如同潜在的纤溶酶原激活物抑制剂-1。这两个分子通过活性分子的反应环相连,该反应环取代了潜在分子中另一个β折叠的一条链。
该结构以及确定的影响其肝素亲和力的突变,使得能够在分子上定位肝素结合位点。两种形式抗凝血酶的构象展示了丝氨酸蛋白酶抑制剂中反应环的非凡流动性,并为抑制活性所需的环折叠以及肝素对其潜在修饰提供了见解。二聚化机制与在与变异丝氨酸蛋白酶抑制剂相关疾病中观察到的聚合反应有关。